{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:30:52Z","timestamp":1768887052004,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10067-022-06145-8","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:04:46Z","timestamp":1648631086000},"page":"2053-2063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-7007","authenticated-orcid":false,"given":"Hatice","family":"Bodur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-9233","authenticated-orcid":false,"given":"Fatma Gul","family":"Yurdakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-3825","authenticated-orcid":false,"given":"Sebnem","family":"Ataman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-7482","authenticated-orcid":false,"given":"Hasan Fatih","family":"Cay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-2264","authenticated-orcid":false,"given":"Gulcan","family":"Gurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-5934","authenticated-orcid":false,"given":"Erhan","family":"Capkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-2108","authenticated-orcid":false,"given":"\u0130lhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-2788","authenticated-orcid":false,"given":"Mehmet Tuncay","family":"Duruoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-9470","authenticated-orcid":false,"given":"Meltem Alkan","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-3854","authenticated-orcid":false,"given":"Aylin","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5988-7369","authenticated-orcid":false,"given":"Ilker","family":"Yagci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-5991","authenticated-orcid":false,"given":"Feride","family":"Gogus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-7250","authenticated-orcid":false,"given":"Ayhan","family":"Kamanli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-2968","authenticated-orcid":false,"given":"Ozgur","family":"Akgul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-1586","authenticated-orcid":false,"given":"Remzi","family":"Cevik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"6145_CR1","doi-asserted-by":"publisher","unstructured":"Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew\u00e9 R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D (2019) A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71:1101-1111.: https:\/\/doi.org\/10.1002\/art.40866","DOI":"10.1002\/art.40866"},{"key":"6145_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10067-020-05209-x","volume":"40","author":"S Rodrigues-Manica","year":"2021","unstructured":"Rodrigues-Manica S, Silva J, Cruz-Machado R, Coelho C, Duarte J, Vieira-Sousa E, Tavares-Costa J, Pimentel-Santos FM (2021) Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. Clin Rheumatol 40:33\u201341. https:\/\/doi.org\/10.1007\/s10067-020-05209-x","journal-title":"Clin Rheumatol"},{"key":"6145_CR3","doi-asserted-by":"publisher","unstructured":"Sieper J, Landew\u00e9 R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A (2019) Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 7;5:e000917.: https:\/\/doi.org\/10.1136\/rmdopen-2019-000917","DOI":"10.1136\/rmdopen-2019-000917"},{"key":"6145_CR4","doi-asserted-by":"publisher","unstructured":"Shimabuco AY, Gon\u00e7alves CR, Moraes JCB, Waisberg MG, Ribeiro ACM, Sampaio-Barros PD, Goldenstein-Schainberg C, Bonfa E, Saad CGS (2018) Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors. Adv Rheumatol. 4;58:40.: https:\/\/doi.org\/10.1186\/s42358-018-0040-x","DOI":"10.1186\/s42358-018-0040-x"},{"key":"6145_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen X, Zhang T, Wang W, Xue J (2018) Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin Rheumatol 37:1625\u20131632. https:\/\/doi.org\/10.1007\/s10067-018-4084-4","journal-title":"Clin Rheumatol"},{"key":"6145_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","volume":"47","author":"DJ Pradeep","year":"2008","unstructured":"Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C (2008) Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47:1726\u20131727. https:\/\/doi.org\/10.1093\/rheumatology\/ken334","journal-title":"Rheumatology (Oxford)"},{"key":"6145_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","volume":"160","author":"G Haberhauer","year":"2010","unstructured":"Haberhauer G, Strehblow C, Fasching P (2010) Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr 160:220\u20134. https:\/\/doi.org\/10.1007\/s10354-010-0795-0","journal-title":"Wien Med Wochenschr"},{"key":"6145_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1080\/14397595.2017.1367076","volume":"28","author":"S Monti","year":"2018","unstructured":"Monti S, Todoerti M, Codullo V, Favalli EG, Biggioggero M, Becciolini A, Montecucco C, Caporali R (2018) Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol 28:542\u2013549. https:\/\/doi.org\/10.1080\/14397595.2017.1367076","journal-title":"Mod Rheumatol"},{"key":"6145_CR9","doi-asserted-by":"publisher","unstructured":"Landew\u00e9 R, van Tubergen A (2015) Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 17:47.:https:\/\/doi.org\/10.1007\/s11926-015-0522-3","DOI":"10.1007\/s11926-015-0522-3"},{"key":"6145_CR10","doi-asserted-by":"publisher","unstructured":"Machado PM, Deodhar A (2019). Treat-to-target in axial spondyloarthritis: gold standard or fools\u2019 gold? Curr Opin Rheumatol. 31:344\u2013348.:https:\/\/doi.org\/10.1097\/BOR.0000000000000625","DOI":"10.1097\/BOR.0000000000000625"},{"key":"6145_CR11","doi-asserted-by":"publisher","unstructured":"Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landew\u00e9 RB (2014) The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration\u2019s comments and concerns. Arthritis Rheumatol. 66:2649\u20132656.:https:\/\/doi.org\/10.1002\/art.38776","DOI":"10.1002\/art.38776"},{"key":"6145_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.berh.2014.10.005","volume":"28","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:807\u2013818. https:\/\/doi.org\/10.1016\/j.berh.2014.10.005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6145_CR13","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Breijo B, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n V, Mart\u00ednez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A (2019) Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther. 211:66.:https:\/\/doi.org\/10.1186\/s13075-019-1849-3","DOI":"10.1186\/s13075-019-1849-3"},{"key":"6145_CR14","doi-asserted-by":"publisher","unstructured":"Carvalho PD, Ruyssen-Witrand A, Fonseca J, Marreiros A, Machado PM (2020) Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort. RMD Open. 6:e001356.:https:\/\/doi.org\/10.1136\/rmdopen-2020-001356","DOI":"10.1136\/rmdopen-2020-001356"},{"key":"6145_CR15","doi-asserted-by":"publisher","unstructured":"Akgul O, Bodur H, Ataman S, Yurdakul FG, Capkin E, Gurer G, Sezer I, Duruoz MT, Melikoglu MA, Cay HF, Rezvani A, Yagci I, Gogus F, Kamanli A, Cevik R (2020) Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry. Rheumatol Int. 40:1793\u20131801.:https:\/\/doi.org\/10.1007\/s00296-020-04680-8","DOI":"10.1007\/s00296-020-04680-8"},{"key":"6145_CR16","doi-asserted-by":"publisher","unstructured":"Landew\u00e9 RB, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, Bauer L, Hoepken B, Davies OR, de Peyrecave N, Thomas K, Gensler LS (2020) Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis. 79:920\u2013928.:https:\/\/doi.org\/10.1136\/annrheumdis-2019-216839","DOI":"10.1136\/annrheumdis-2019-216839"},{"key":"6145_CR17","doi-asserted-by":"publisher","unstructured":"Landew\u00e9 R, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch F, Gaffney K, Bauer L, Hoepken B, de Peyrecave N, Thomas K, Gensler LS (2020) Induction of sustained clinical remission in early axial spondyloarthritis following certolizumabpegol treatment: 48-week outcomes from C-OPTIMISE. Rheumatol Ther. 7:581\u2013599.: https:\/\/doi.org\/10.1007\/s40744-020-00214-7.","DOI":"10.1007\/s40744-020-00214-7"},{"key":"6145_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3899\/jrheum.140811","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Marchesoni A, D\u2019Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-a drugs: an Italian multicenter study. J Rheumatol 42:258\u2013263","journal-title":"J Rheumatol"},{"key":"6145_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA et al (2014) The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol 41:1095\u20131103","journal-title":"J Rheumatol"},{"key":"6145_CR20","unstructured":"Zochling J, Braun J (2006) Remission in ankylosing spondylitis. Clin Exp Rheumatol. 24:S-88\u201392."},{"key":"6145_CR21","doi-asserted-by":"publisher","unstructured":"Ziade N, Abi Karam G, Merheb G, Mallak I, Irani L, Alam E, Messaykeh J, Menassa J, Mroue\u2019 K, Uthman I, Masri AF, Ghorra P, Witte T, Baraliakos X (2019) HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. Int J Rheum Dis. 22:708\u2013714.:https:\/\/doi.org\/10.1111\/1756-185X.13487.","DOI":"10.1111\/1756-185X.13487"},{"key":"6145_CR22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00296-015-3342-x","volume":"35","author":"A Akassou","year":"2015","unstructured":"Akassou A, Yacoubi H, Jamil A, Dakka N, Amzazi S, Sadki K, Niamane R, Elhassani S, Bakri Y (2015) Prevalence of HLA-B27 in Moroccan healthy subjects and patients with ankylosing spondylitis and mapping construction of several factors influencing AS diagnosis by using multiple correspondence analysis. Rheumatol Int 35:1889\u201394. https:\/\/doi.org\/10.1007\/s00296-015-3342-x","journal-title":"Rheumatol Int"},{"key":"6145_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jbspin.2020.03.012","volume":"87","author":"M Ar\u00e9valo","year":"2020","unstructured":"Ar\u00e9valo M, L\u00f3pez-Medina C, Moreno Martinez-Losa M, Molt\u00f3 A, Font P, Collantes-Estevez E, Gratac\u00f3s J (2020) Role of HLA-B27 in the comorbidities observed in axial spondyloarthritis: data from COMOSPA. Joint Bone Spine 87:445\u2013448. https:\/\/doi.org\/10.1016\/j.jbspin.2020.03.012","journal-title":"Joint Bone Spine"},{"key":"6145_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5152\/eurjrheum.2019.18180","volume":"6","author":"AP K\u0131saarslan","year":"2019","unstructured":"K\u0131saarslan AP, S\u00f6zeri B, G\u00fcnd\u00fcz Z, Zarars\u0131z G, Poyrazo\u011flu H, D\u00fc\u015f\u00fcnsel R (2019) Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis. Eur J Rheumatol 6:130\u201335. https:\/\/doi.org\/10.5152\/eurjrheum.2019.18180","journal-title":"Eur J Rheumatol"},{"key":"6145_CR25","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1111\/1756-185X.13375","volume":"21","author":"M Soubrier","year":"2018","unstructured":"Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ (2018) Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France). Int J Rheum Dis 21:1986\u20131992. https:\/\/doi.org\/10.1111\/1756-185X.13375","journal-title":"Int J Rheum Dis"},{"key":"6145_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5114\/reum.2017.69775","volume":"55","author":"A Sebastian","year":"2017","unstructured":"Sebastian A, Wojtala P, Lubi\u0144ski \u0141, Mimier M, Chlebicki A, Wiland P (2017) Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. Reumatologia 55:157\u2013162. https:\/\/doi.org\/10.5114\/reum.2017.69775","journal-title":"Reumatologia"},{"key":"6145_CR27","doi-asserted-by":"publisher","unstructured":"Landew\u00e9 R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 392:134\u2013144.: https:\/\/doi.org\/10.1016\/S0140-6736(18)31362-X.","DOI":"10.1016\/S0140-6736(18)31362-X"},{"key":"6145_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40744-020-00208-5","volume":"7","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Sandoval D, Holdsworth E, Booth N, Hunter T (2020) Use and switching of biologic therapy in patients with non-radiographic axial spondyloarthritis: a patient and provider survey in the United States. Rheumatol Ther 7:415\u2013423. https:\/\/doi.org\/10.1007\/s40744-020-00208-5","journal-title":"Rheumatol Ther"},{"key":"6145_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72:1149\u20131155. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201933","journal-title":"Ann Rheum Dis"},{"issue":"161","key":"6145_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/OARRR.S179472","volume":"10","author":"W Hartung","year":"2018","unstructured":"Hartung W, Nigg A, Strunk J, Wolff B (2018) Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice Open Access. Rheumatol 10(161):169. https:\/\/doi.org\/10.2147\/OARRR.S179472","journal-title":"Rheumatol"},{"key":"6145_CR31","doi-asserted-by":"publisher","unstructured":"Palominos PE, de Campos APB, Ribeiro SLE, Xavier RM, Xavier JW, de Oliveira FB, Guerra B, Saldanha C, Mancuso ACB, Kohem CL, Gasparin AA, Sampaio-Barros PD (2019) Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. Adv Rheumatol. 59:23.:https:\/\/doi.org\/10.1186\/s42358-019-0066-8.","DOI":"10.1186\/s42358-019-0066-8"},{"key":"6145_CR32","doi-asserted-by":"publisher","unstructured":"Berg KH, Rohde G, Pripp A, Pr\u00f8ven A, Pirelli Benestad EE, \u00d8stensen M, Haugeberg G (2021) Increased proportion of comorbidities but no deterioration of sexual QOL during a 5-year follow-up in patients with axSpA in the biologic treatment era. Rheumatology (Oxford). 7: keaa887.:https:\/\/doi.org\/10.1093\/rheumatology\/keaa887","DOI":"10.1093\/rheumatology\/keaa887"},{"key":"6145_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47:343\u2013350. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.005","journal-title":"Semin Arthritis Rheum"},{"key":"6145_CR34","doi-asserted-by":"publisher","unstructured":"Lee S, Park YJ, Lee JY (2019) The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis. J Korean Med Sci. 4:e278.:https:\/\/doi.org\/10.3346\/jkms.2019.34.e278.","DOI":"10.3346\/jkms.2019.34.e278"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06145-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T11:16:20Z","timestamp":1654859780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06145-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6145"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06145-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}